ISTH/LinkedIn
Sep 8, 2026, 07:02
Emerging Therapies in Thrombosis – Factor XI/XIa Inhibitor Trials – ISTH
International Society on Thrombosis and Haemostasis (ISTH) shared a post on LinkedIn:
“From the coagulation cascade to the latest clinical trials, take a closer look at the evolving science of Factor XI and Factor XIa inhibition.
In this on-demand session, Dr. Weitz provides a concise overview of FXI/FXIa inhibitors and compares some of the leading investigational therapies currently under evaluation.
See the evidence come to life through animated charts highlighting recent clinical data, study findings and the potential implications for anticoagulant therapy.
What could this emerging therapeutic approach mean for clinical practice?”
Other posts featuring ISTH on Hemostasis Today.
-
Oct 17, 2026, 17:27John Strouse: Building Standards for Whole-Person Sickle Cell Care Through Collaboration
-
Oct 17, 2026, 17:20Jean-Jacques Kiladjian: Exploring the Future of Polycythemia Vera Treatment at MPN Horizons 2026
-
Oct 17, 2026, 17:10Habib Bennaceur: Strengthening Collaboration in Haemophilia, Sickle Cell Disease and Thalassaemia in India
-
Oct 17, 2026, 16:58Danny Hsu: Building Connections at the AUSNBled Collaborative Dinner in Auckland
-
Oct 17, 2026, 16:48Kalyan Roy: Enhancing Patient Experience Through Learning and Collaboration
-
Oct 17, 2026, 16:43Wilfried Dinh: Antiplatelet Therapy in 2026: Duration is Becoming a Dynamic Decision
-
Oct 17, 2026, 16:37Ian Setchfield: Dr. Evans Presents on Safe Anticoagulation Prescribing at East Kent Hospitals
-
Oct 17, 2026, 16:33Lewis Thomas: Connecting Through Shared Experiences at ASCAT 2026
-
Oct 17, 2026, 16:29Nilesh Jethwa: Yasmin Adverse Event Reports Exceed 23,000 Over Two-Year Period